Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway

Background: Doxorubicin (Dox) can induce endotheliotoxicity and damage the vascular endothelium (VE). The most principle mechanism might be excess reactive oxygen species (ROS) generation. Nevertheless, the characteristics of ROS generation, downstream mechanisms, and target organelles in Dox-induce...

Full description

Bibliographic Details
Main Authors: Huan He, Liang Wang, Yang Qiao, Qing Zhou, Hongwei Li, Shuping Chen, Dong Yin, Qing Huang, Ming He
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01531/full
id doaj-ec0890de18aa4277a14d6a836a7234c0
record_format Article
spelling doaj-ec0890de18aa4277a14d6a836a7234c02020-11-25T02:55:44ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-01-011010.3389/fphar.2019.01531485392Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO PathwayHuan He0Huan He1Liang Wang2Yang Qiao3Qing Zhou4Hongwei Li5Shuping Chen6Dong Yin7Qing Huang8Ming He9Jiangxi Provincial Institute of Hypertension, The First Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang University School of Pharmaceutical Science, Nanchang, ChinaDepartment of Rehabilitation, The First Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang University School of Pharmaceutical Science, Nanchang, ChinaJiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang University School of Pharmaceutical Science, Nanchang, ChinaJiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang University School of Pharmaceutical Science, Nanchang, ChinaJiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang University School of Pharmaceutical Science, Nanchang, ChinaJiangxi Provincial Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Provincial Institute of Cardiovascular Diseases, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, Nanchang, ChinaJiangxi Provincial Institute of Hypertension, The First Affiliated Hospital of Nanchang University, Nanchang, ChinaBackground: Doxorubicin (Dox) can induce endotheliotoxicity and damage the vascular endothelium (VE). The most principle mechanism might be excess reactive oxygen species (ROS) generation. Nevertheless, the characteristics of ROS generation, downstream mechanisms, and target organelles in Dox-induced endotheliotoxicity have yet to be elucidated.Methods and Results: In order to explore the related problems, the VE injury models were established in mice and human umbilical vein endothelial cells (HUVECs) by Dox-induced endotheliotoxicity. Results showed that the activities of lactate dehydrogenase (LDH) and creatine kinase of mice’s serum increased after injected Dox. The thoracic aortic strips’ endothelium-dependent dilation was significantly impaired, seen noticeable inflammatory changes, and brown TUNEL-positive staining in microscopy. After Dox-treated, HUVECs viability lowered, LDH and caspase-3 activities, and apoptotic cells increased. Both intracellular/mitochondrial ROS generation significantly increased, and intracellular ROS generation lagged behind mitochondria. HUVECs treated with Dox plus ciclosporin A (CsA) could basically terminate ROS burst, but plus edaravone (Eda) could only delay or inhibit, but could not completely cancel ROS burst. Meanwhile, the expression of endothelial nitric oxide synthase (eNOS) decreased, especially phosphorylation of eNOS significantly. Then nitric oxide content decreased, the mitochondrial function was impaired, mitochondrial membrane potential (MMP) impeded, mitochondrial swelled, mitochondrial permeability transition pore (mPTP) was opened, and cytochrome C was released from mitochondria into the cytosol.Conclusion: Dox produces excess ROS in the mitochondria, thereby weakens the MMP, opens mPTP, activates the ROS-induced ROS release mechanism, induces ROS burst, and leads to mitochondrial dysfunction, which in turn damages VE. Therefore, interrupting any step of the cycles, as mentioned above can end the related vicious cycle and prevent the occurrence and development of injury.https://www.frontiersin.org/article/10.3389/fphar.2019.01531/fulldoxorubicinvascular endotheliumendotheliotoxicitymitochondriaROS/eNOS/NO pathway
collection DOAJ
language English
format Article
sources DOAJ
author Huan He
Huan He
Liang Wang
Yang Qiao
Qing Zhou
Hongwei Li
Shuping Chen
Dong Yin
Qing Huang
Ming He
spellingShingle Huan He
Huan He
Liang Wang
Yang Qiao
Qing Zhou
Hongwei Li
Shuping Chen
Dong Yin
Qing Huang
Ming He
Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway
Frontiers in Pharmacology
doxorubicin
vascular endothelium
endotheliotoxicity
mitochondria
ROS/eNOS/NO pathway
author_facet Huan He
Huan He
Liang Wang
Yang Qiao
Qing Zhou
Hongwei Li
Shuping Chen
Dong Yin
Qing Huang
Ming He
author_sort Huan He
title Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway
title_short Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway
title_full Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway
title_fullStr Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway
title_full_unstemmed Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway
title_sort doxorubicin induces endotheliotoxicity and mitochondrial dysfunction via ros/enos/no pathway
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2020-01-01
description Background: Doxorubicin (Dox) can induce endotheliotoxicity and damage the vascular endothelium (VE). The most principle mechanism might be excess reactive oxygen species (ROS) generation. Nevertheless, the characteristics of ROS generation, downstream mechanisms, and target organelles in Dox-induced endotheliotoxicity have yet to be elucidated.Methods and Results: In order to explore the related problems, the VE injury models were established in mice and human umbilical vein endothelial cells (HUVECs) by Dox-induced endotheliotoxicity. Results showed that the activities of lactate dehydrogenase (LDH) and creatine kinase of mice’s serum increased after injected Dox. The thoracic aortic strips’ endothelium-dependent dilation was significantly impaired, seen noticeable inflammatory changes, and brown TUNEL-positive staining in microscopy. After Dox-treated, HUVECs viability lowered, LDH and caspase-3 activities, and apoptotic cells increased. Both intracellular/mitochondrial ROS generation significantly increased, and intracellular ROS generation lagged behind mitochondria. HUVECs treated with Dox plus ciclosporin A (CsA) could basically terminate ROS burst, but plus edaravone (Eda) could only delay or inhibit, but could not completely cancel ROS burst. Meanwhile, the expression of endothelial nitric oxide synthase (eNOS) decreased, especially phosphorylation of eNOS significantly. Then nitric oxide content decreased, the mitochondrial function was impaired, mitochondrial membrane potential (MMP) impeded, mitochondrial swelled, mitochondrial permeability transition pore (mPTP) was opened, and cytochrome C was released from mitochondria into the cytosol.Conclusion: Dox produces excess ROS in the mitochondria, thereby weakens the MMP, opens mPTP, activates the ROS-induced ROS release mechanism, induces ROS burst, and leads to mitochondrial dysfunction, which in turn damages VE. Therefore, interrupting any step of the cycles, as mentioned above can end the related vicious cycle and prevent the occurrence and development of injury.
topic doxorubicin
vascular endothelium
endotheliotoxicity
mitochondria
ROS/eNOS/NO pathway
url https://www.frontiersin.org/article/10.3389/fphar.2019.01531/full
work_keys_str_mv AT huanhe doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway
AT huanhe doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway
AT liangwang doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway
AT yangqiao doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway
AT qingzhou doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway
AT hongweili doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway
AT shupingchen doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway
AT dongyin doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway
AT qinghuang doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway
AT minghe doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway
_version_ 1724716557081247744